85-0.98) for TE, 0.91 (95% Cl: 0.83-1.00) for PQE and 0.91 (95% Cl: 0.84-0.99) for TE and 0.88 (95% CI: 0.80-0.96) for PQE and 0.85 (95% Cl: 0.73-0.97) for TE when comparing F0 versus F1-F4, F0-F1 versus F2- F4, F0-F2 versus F3-F4 and F0-F3 versus F4, respectively. Differences among PQE and TE AUCs were not statistically significant. CONCLUSIONS: This study shows that PQE is a reliable noninvasive method to assess LF, with a diagnostic performance not significantly different

buy Acalabrutinib from TE. Compared to TE, PQE has the advantage of compute measurements visualizing in real-time the explored area. Disclosures: Pietro Andreone – Advisory Committees or Review Panels: Roche, Janssen-Cilag, Gilead, MSD/Schering-Plough; Grant/Research Support: Roche, Gilead; Speaking and Teaching: Roche, MSD/Schering-Plough The following people have nothing to disclose: Erica Fiorini, Fabio Conti, Elena Mazzotta, Chiara De Molo, Silvia Righi, Gabriella Verucchi, Antonietta D’Errico, Marco Lenzi, Claudia Sama, Carla Serra Background & Aim: Acoustic see more radiation force impulse (ARFI) imaging is a novel non-invasive ultrasound-based method for the evaluation of liver fibrosis and cirrhosis. The relevance of ARFI imaging for outcome of patients with liver cirrhosis has not been established

so far. Methods: In this prospective study, consecutive patients with established liver cirrhosis from different etiologies underwent ARFI imaging of the liver and spleen and transient elastography (TE) of the liver. Liver and spleen stiffness measurements were compared with overall survival time or time to transplantation using Cox regression analyses. Results: 158 patients (mean age: 54± 11; male gender: 66.5%; Child-Pugh score B/C: 46%) were included in the study. The median liver and spleen stiffness measured by ARFI was 3.0 m/s and 3.7 m/s, respectively. MCE The median liver stiffness measured by TE was 36.3 kPa. The mean duration of follow-up was 629±390 days. During the follow-up

period 44/158 patients died and 25/158 underwent liver transplantation. There was a significant association between stiffness values obtained with all three methods and survival, i. e. patients with higher stiffness values showed shorter survival times. However, in a multivariate Cox regression analysis that included all three modalities, only spleen stiffness measured by ARFI was independently associated with survival (p=0.008; HR: 2.1, 95% Cl: 1.2-3.6). The AUROC of spleen stiffness measurements by ARFI for the prediction of survival was 0.64 (p=0.003). Conclusions: Spleen stiffness measured by ARFI predicts survival in patients with liver cirrhosis. Disclosures: Christoph Sarrazin – Advisory Committees or Review Panels: Boehringer Ingelheim, Vertex, Janssen, Merck/MSD, Gilead, Roche, Boehringer Ingelheim, Achillion, JaPharmaceuticals, Merck & Co.